BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Feb. 13, 2019-- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the three months ended
BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Feb. 6, 2019-- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2018 third fiscal quarter
BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Jan. 15, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that it will host its first R&D Day for investors and analysts in New
BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Jan. 3, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, announced the company enrolled its first patient in a Phase 2a clinical trial evaluating
